U.S. Markets closed

CanSino Biologics Inc. (6185.HK)

HKSE - HKSE Delayed Price. Currency in HKD
Add to watchlist
329.000+18.000 (+5.79%)
At close: 4:08PM HKT
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close311.000
Open310.000
Bid327.000 x 0
Ask329.000 x 0
Day's Range302.800 - 329.000
52 Week Range141.100 - 449.600
Volume2,652,991
Avg. Volume1,761,177
Market Cap105.945B
Beta (5Y Monthly)-0.75
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Virtual Conference for Life Sciences Companies Broadcast Live June 24th, 2021
    GlobeNewswire

    Virtual Conference for Life Sciences Companies Broadcast Live June 24th, 2021

    Company executives will share corporate vision and answer audience questions at LifeSciencesInvestorForum.comNEW YORK, June 21, 2021 (GLOBE NEWSWIRE) -- Life Sciences Investor Forum today announced the agenda for its quarterly event for public and private companies, investors and industry professionals from around the world. This day-long virtual event will showcase live company presentations and interactive discussions focused on the life sciences industry. Individual investors, institutional i

  • Shield Therapeutics PLC (“Shield”) to Webcast Live at Life Sciences Investor Forum June 24th
    GlobeNewswire

    Shield Therapeutics PLC (“Shield”) to Webcast Live at Life Sciences Investor Forum June 24th

    Shield invites individual and institutional investors, as well as advisors and analysts, to attend real-time, interactive presentations on LifeSciencesInvestorForum.comLONDON, June 21, 2021 (GLOBE NEWSWIRE) -- Shield Therapeutics PLC (STX.L), based in Newcastle-upon-Tyne, UK, focused on addressing iron deficiency with its lead product Feraccru®/Accrufer® (ferric maltol), today announced that Greg Madison, Chief Executive Officer, will present live at LifeSciencesInvestorForum.com on June 24th. D

  • PR Newswire

    CanSinoBIO Receives European GMP Certification for its COVID-19 Vaccine Convidecia™

    CanSino Biologics Inc. ("CanSinoBIO") (SHSE: 688185, HKEX: 06185) today announced that its Recombinant Novel Coronavirus Vaccine, (Adenovirus Type 5 Vector) ("Ad5-nCoV", trade name: Convidecia™), has been granted a Good Manufacturing Practice ("GMP") certificate by the Hungarian National Institute of Pharmacy and Nutrition (OGYÉI). The certification was issued on May 21, 2021 after a thorough inspection of CanSinoBIO's production of Convidecia™.